Ionis’s inhaled antisense candidate shows promising signs, with Arrowhead and Translate Bio also in the running.
The company becomes the third in two months to buy back a division it had spun out just a few years earlier.
The next big approach in Alzheimer’s has been dealt a blow, and there are plenty more tau-targeting contenders.
A virtual ESC sees Vascepa’s plaque reduction, Ionis’s second-gen candidates and Medtronic’s cryoblation win.
All the attention is on aducanumab, but yesterday’s deal with Denali is a reminder that Biogen has other irons in the fire.
The deal between Sangamo and Biogen marks another endorsement of a gene-editing technology that many had written off years ago.